EE04025B1 - Heterodimeere moodustavad hübriidvalgud - Google Patents

Heterodimeere moodustavad hübriidvalgud

Info

Publication number
EE04025B1
EE04025B1 EE9800256A EE9800256A EE04025B1 EE 04025 B1 EE04025 B1 EE 04025B1 EE 9800256 A EE9800256 A EE 9800256A EE 9800256 A EE9800256 A EE 9800256A EE 04025 B1 EE04025 B1 EE 04025B1
Authority
EE
Estonia
Prior art keywords
subunit
heterodimers
coexpressed
sequence contains
fusion proteins
Prior art date
Application number
EE9800256A
Other languages
English (en)
Estonian (et)
Other versions
EE9800256A (et
Inventor
A. Jameson Bradford
C. Chappel Scott
K. Campbell Robert
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE9800256A publication Critical patent/EE9800256A/xx
Publication of EE04025B1 publication Critical patent/EE04025B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/22Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of other functional groups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EE9800256A 1996-02-20 1997-02-20 Heterodimeere moodustavad hübriidvalgud EE04025B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1193696P 1996-02-20 1996-02-20
PCT/US1997/002315 WO1997030161A1 (en) 1996-02-20 1997-02-20 Hybrid proteins which form heterodimers

Publications (2)

Publication Number Publication Date
EE9800256A EE9800256A (et) 1999-02-15
EE04025B1 true EE04025B1 (et) 2003-04-15

Family

ID=21752599

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800256A EE04025B1 (et) 1996-02-20 1997-02-20 Heterodimeere moodustavad hübriidvalgud

Country Status (25)

Country Link
US (5) US6193972B1 (hu)
EP (1) EP0894141B1 (hu)
JP (2) JP4140927B2 (hu)
KR (1) KR100369985B1 (hu)
CN (1) CN1261579C (hu)
AT (1) ATE295887T1 (hu)
AU (1) AU706504B2 (hu)
BG (1) BG64510B1 (hu)
BR (1) BR9707589A (hu)
CA (1) CA2245877C (hu)
CZ (1) CZ291212B6 (hu)
DE (1) DE69733309T2 (hu)
DK (1) DK0894141T3 (hu)
EA (1) EA002474B1 (hu)
EE (1) EE04025B1 (hu)
ES (1) ES2241040T3 (hu)
HU (1) HUP9900619A3 (hu)
IL (1) IL125864A (hu)
NO (1) NO321777B1 (hu)
NZ (1) NZ331539A (hu)
PL (1) PL187400B1 (hu)
PT (1) PT894141E (hu)
SK (1) SK282326B6 (hu)
UA (1) UA52646C2 (hu)
WO (1) WO1997030161A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030161A1 (en) * 1996-02-20 1997-08-21 Applied Research Systems Ars Holding N.V. Hybrid proteins which form heterodimers
US6635740B1 (en) * 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
US6844161B2 (en) 1997-09-04 2005-01-18 Gryphon Therapeutics, Inc. Modular protein libraries and methods of preparation
AU783320B2 (en) * 2000-02-22 2005-10-13 Merck Serono Sa Process of purification of hCG and recombinant hCG purified by that method
US20030228600A1 (en) * 2000-07-14 2003-12-11 Eppendorf 5 Prime, Inc. DNA isolation method and kit
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Bcmaポリペプチド及びその使用
PL1885753T3 (pl) 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
WO2009039409A1 (en) * 2007-09-21 2009-03-26 The Regents Of The University Of Californina Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20110003711A1 (en) * 2008-02-01 2011-01-06 Chromocell Corporation Cell lines expressing gaba receptor and methods using them
CN102002495B (zh) * 2009-08-31 2012-07-18 成都蓉生药业有限责任公司 用于表达异二聚体糖蛋白激素的表达框、表达载体及制备方法
CA2812739A1 (en) * 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
BR112020026112A2 (pt) * 2018-06-21 2021-04-06 Shattuck Labs, Inc. Proteínas heterodiméricas e usos das mesmas
CA3136992A1 (en) * 2019-05-24 2020-12-03 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092468T3 (es) * 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0670730B1 (en) 1992-03-30 2003-06-04 Immunex Corporation Fusion protein comprising two tumor necrosis factor receptors
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US6194177B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
WO1997030161A1 (en) * 1996-02-20 1997-08-21 Applied Research Systems Ars Holding N.V. Hybrid proteins which form heterodimers

Also Published As

Publication number Publication date
JP4140927B2 (ja) 2008-08-27
DK0894141T3 (da) 2005-08-22
US6193972B1 (en) 2001-02-27
JP2008019258A (ja) 2008-01-31
US6663867B2 (en) 2003-12-16
NO983799D0 (no) 1998-08-19
US7291339B2 (en) 2007-11-06
EE9800256A (et) 1999-02-15
HUP9900619A2 (hu) 1999-06-28
CN1212017A (zh) 1999-03-24
EP0894141B1 (en) 2005-05-18
US20100075402A1 (en) 2010-03-25
CZ264498A3 (cs) 1998-12-16
PL187400B1 (pl) 2004-06-30
AU706504B2 (en) 1999-06-17
CA2245877A1 (en) 1997-08-21
NO321777B1 (no) 2006-07-03
ATE295887T1 (de) 2005-06-15
US20010014333A1 (en) 2001-08-16
DE69733309D1 (de) 2005-06-23
PT894141E (pt) 2005-09-30
UA52646C2 (uk) 2003-01-15
EA199800744A1 (ru) 1999-02-25
BR9707589A (pt) 2000-01-04
SK114898A3 (en) 1999-07-12
NO983799L (no) 1998-10-19
ES2241040T3 (es) 2005-10-16
IL125864A (en) 2007-07-04
NZ331539A (en) 2000-01-28
AU2125297A (en) 1997-09-02
BG102705A (en) 1999-04-30
EA002474B1 (ru) 2002-06-27
KR100369985B1 (ko) 2004-03-26
CZ291212B6 (cs) 2003-01-15
EP0894141A1 (en) 1999-02-03
WO1997030161A1 (en) 1997-08-21
BG64510B1 (bg) 2005-05-31
CN1261579C (zh) 2006-06-28
HUP9900619A3 (en) 2001-11-28
JP2000504586A (ja) 2000-04-18
US20090240039A1 (en) 2009-09-24
US20040230034A1 (en) 2004-11-18
IL125864A0 (en) 1999-04-11
KR19990082482A (ko) 1999-11-25
SK282326B6 (sk) 2002-01-07
CA2245877C (en) 2013-09-03
PL328454A1 (en) 1999-02-01
DE69733309T2 (de) 2006-01-19

Similar Documents

Publication Publication Date Title
EE04025B1 (et) Heterodimeere moodustavad hübriidvalgud
ATE393222T1 (de) Dcr3 polypeptid, ein tnfr homolog
DK0619839T3 (da) Nye polypeptider til fremme af cellebinding
DE69535641D1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
DE69737415D1 (de) Gespannte, helixformende peptide und verfahren um sie herzustellen
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
EP2829549A3 (en) Hybrid and tandem expression of neisserial derived proteins
DE3855536D1 (de) Rezeptoren für wachstumshormone
AR046833A1 (es) Anticuerpos anti-interleuquina-10
BR0313331A (pt) antagonistas de receptor de nogo
IS8339A (is) Mótlyf viðtaka NOGO
WADA et al. Primary structures of and genes for new ribosomal proteins A and B in Escherichia coli
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
EP0180878A3 (en) Heterodimeric t lymphocyte receptor
CA2440596A1 (en) Soluble heterodimeric cytokine receptor
EA199800885A1 (ru) Модуляторы связанного с рецептором tnf-фактора (traf), их получение и изменение
Katsoyannis et al. Insulin Peptides. XII. Human Insulin Generation by Combination of Synthetic A and B Chains1
EA200000685A1 (ru) Комплекс ifnar2/ifn
ES549185A0 (es) Procedimiento para sintetizar peptidos a partir de aminoaci-dos
Paul et al. Design of a natural cis peptide bond motif to form type VI β-turn mimetic
KR970070198A (ko) 항-파스 재조합 항체 및 이에 대한 디엔아이
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
EA200600376A1 (ru) Антагонисты nogo-рецептора
DE69635161D1 (de) Rekombinante hetero-multimerische proteine von dem alpha-beta c4 bp typ
EP1557432A3 (en) Hybrid proteins which form heterodimers

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090220